AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Actinium Pharmaceuticals, Inc
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SV3L17
1.52▼ 0.08 (-5.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.60
Day's Range
1.47 – 1.63
52-Week Range
0.74 – 1.74
Volume
241.9K
Avg Volume
194.7K
Share Statistics
Shares Outstanding
Employees
25
Exchange
XASE
Listed
2007-07-19
Share count as of August 6, 2026

Actinium Pharmaceuticals, Inc (ATNM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Actinium Pharmaceuticals, Inc (ATNM)
What is Actinium Pharmaceuticals, Inc's Market Cap?
Actinium Pharmaceuticals, Inc's Market Cap is $47.8M, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's Enterprise Value?
Actinium Pharmaceuticals, Inc's Enterprise Value is $5.7M, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's Price / Sales?
Actinium Pharmaceuticals, Inc's Price / Sales is 531.0×, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's EV / Revenue?
Actinium Pharmaceuticals, Inc's EV / Revenue is 63.0×, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's EV / EBITDA?
Actinium Pharmaceuticals, Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's Revenue (TTM)?
Actinium Pharmaceuticals, Inc's Revenue (TTM) is $90.0K, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's Net Income (TTM)?
Actinium Pharmaceuticals, Inc's Net Income (TTM) is -$23.5M, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's EBITDA?
Actinium Pharmaceuticals, Inc's EBITDA is -$25.4M, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's Diluted EPS (TTM)?
Actinium Pharmaceuticals, Inc's Diluted EPS (TTM) is -0.75, based on as-reported figures from SEC (XBRL) filings.
What is Actinium Pharmaceuticals, Inc's EBITDA Margin?
Actinium Pharmaceuticals, Inc's EBITDA Margin is -28174.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ATNMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue—
YoY growth————
Operating expenses:
Research and development, net of reimbursements
General and administrative
Total operating expenses
% of revenue21.2%——6424.4%
Income/(Loss) from operations
% of revenue78.8%——-6324.4%
Other income:
Interest income - net
Total other income
Income/(loss) before income taxes———
Net income/(loss)
% of revenue79.7%——-5701.1%
Net income/(loss) per common share – basic (in Dollars per share)
Net income/(loss) per common share – fully diluted (in Dollars per share)